The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.
Patients hospitalized with gram-negative bacteraemia have similar outcomes regardless of whether they receive a 7-day or 14-day course of antibiotic therapy, according to a study presented at ECCMID 2018.
While a 6-day course of flucloxacillin appeared as effective as a 12-day course in curing and reducing short-term risk of relapse among patients hospitalized for cellulitis, the 6-day course led to a greater risk of relapse at 90 days, according to a study from The Netherlands.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Infectious Diseases - Malaysia digital copy today!
Almost a quarter of older patients who are discharged from an acute care hospital and admitted into a post-acute care (PAC) facility carry multidrug-resistant organisms (MDROs) on their hands, show results of a recent study.
New drug applications approved by US FDA as of 01- 15 February 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.